


Gaps in hepatitis testing and monitoring programmes across the EU/EEA

May 31 2017



In the EU/EEA, we see a wide variation in existing national testing policy and practice when it comes to hepatitis B and C but most countries reported more than one type of approach to the funding of HBV/HCV testing. Credit: European Centre for Disease Prevention and Control, ECDC

The survey results suggest a wide variation in existing national testing policy and practice when it comes to hepatitis B and C - with overall

limited monitoring of testing, diagnosis, and treatment across EU/EEA Member States. Many respondents expressed a need for Europe-wide practical guidance on how testing initiatives should be conducted, evaluated, and monitored.

An estimated 9 to 10 million Europeans have been infected with the hepatitis B (HBV) or hepatitis C virus (HCV) in the countries of the European Union and European Economic Area (EU/EEA), and many are unaware of their infection. ECDC undertook two surveys to evaluate needs and priorities to inform a Guidance on HBV/HCV testing and screening in the EU and to assess the availability of [monitoring](#) data on the HBV and HCV epidemic against the core indicators defined in the [WHO Regional Action Plan to eliminate viral hepatitis by 2030](#). 20 (65%) and 21 (68%) Member States responded to the two surveys.

The results suggest a wide variation in HBV/HCV testing policy and practice across the EU/EEA showing significant gaps in available testing [guidance](#) and a lack of national monitoring programmes regarding all aspects of testing, diagnosis, treatment, morbidity, and mortality.

Less than half of the responding EU/EEA countries have dedicated HBV or HCV testing guidance in place (29% and 48% respectively), with the remainder having either a number of policy documents where HBV/HCV is included, or no testing policy at all. Just more than half of the countries had a policy on testing of HBV/HCV among people who inject drugs in place, while other key groups such as commercial sex workers, men who have sex with men and people receiving tattoos or piercings in unregulated settings were mostly omitted.

A need for European-level guidance

At the implementation level, more than three out of four responding countries reported that they felt that risk groups were not targeted

effectively by existing testing programmes. Just over half of responding countries agreed that there is a need for a new European-level testing guidance, in particular guidance on who to [test](#), how to target those at risk, and monitoring and evaluation of testing initiatives.

With regards to monitoring indicators, almost all the responding countries collected some morbidity and mortality data on hepatitis B and C's long term complication, liver cancer.

However data on the HBV or HCV status of the patient was recorded by only a few. The most frequently monitored indicator for HCV was the number of people undergoing treatment (12 countries), whereas the number of those treated for HBV is only monitored in seven countries.

What is more: there are no indicators for hepatitis B or C infection that are monitored routinely by all responding Member States, meaning that further work would be required before any meaningful EU-wide monitoring can be established.

This baseline assessment on the situation in the EU/EEA, despite its limitations due to its the response rate, provides invaluable information towards the development of a planned ECDC Guidance on [hepatitis](#) testing helping to ensure that this new Guidance will focus on the main gaps identified.

More information: [ecdc.europa.eu/en/publications ...
af70113dbb90&ID=1706](https://ecdc.europa.eu/en/publications/_af70113dbb90&ID=1706)

Provided by European Centre for Disease Prevention and Control
(ECDC)

Citation: Gaps in hepatitis testing and monitoring programmes across the EU/EEA (2017, May 31) retrieved 11 May 2024 from

<https://medicalxpress.com/news/2017-05-gaps-hepatitis-programmes-eueea.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.